Tauriga Sciences Inc. (TAUG) 0.0202 $TAUG
Tauriga Sciences Inc. Subsidiary Pilus Energy LLC Receives Approval from the US EPA to Commence Scaled Up Pilot Test
GlobeNewswire - Tue Sep 16, 12:44PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that on September 8, 2014, through its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" , received final approval for its Health and Safety Plan ("H & S Plan" . The approval was granted by the United States Environmental Protection Agency ("EPA" and the project subcontractor Chicago Bridge & Iron (NYSE:CBI) ("CB & I" , which operates the EPA's Test & Evaluation ("T & E" Facility where the next phase of the commercial pilot will take place. This final approval, along with the already approved Quality Assurance Project Plan ("QA Plan" , will enable the Company to commence development scale pilot testing at the EPA T& E Facility. The facility is co-located with the Metropolitan Sewer District of Great Cincinnati's ("MSDGC" largest wastewater treatment plant, on the Mill Creek site, which flows directly into the Ohio river.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Tauriga Sciences, Inc.
GlobeNewswire - Tue Sep 16, 10:22AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on Tauriga Sciences, Inc. (TAUG-OTC). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
Tauriga Sciences Inc. Executes Investment Banking Agreement With Tokyo, Japan Based Dragoon Capital Inc.
GlobeNewswire - Mon Aug 25, 7:30AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it has entered into an investment banking agreement with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. ("Dragoon" . Through this investment banking agreement, Dragoon has agreed on a best efforts basis to secure the Company a private placement equity capital financing from its extensive base of both Japanese institutional and accredited individual investors. The proceeds from this private placement, if and when complete, should enable the Company to expand its medicinal cannabis and complementary natural wellness businesses as well as provide Pilus Energy with capital as it advances its pilot test program with the Metropolitan Sewer District of Greater Cincinnati ("MSDGC" and the EPA T&E department (Environmental Protection Agency's Testing & Evaluation department).
Tauriga Sciences Inc. to Present at Marijuana for Medical Professionals Conference on September 9 in Denver, Colorado
GlobeNewswire - Mon Aug 18, 6:26AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company's Chief Medical Officer, Lawrence A. May, M.D., F.A.C.P., will make a presentation on Tuesday, September 9th, 2014 at 12:15 PM at Marijuana for Medical Professionals Conference being held at the Sherman St Event Center in Denver, CO.
Tauriga Sciences Inc. Subsidiary Honeywood LLC's Berkeley, California Based Headquarters and Production Facility Now Operational
GlobeNewswire - Wed Aug 06, 6:50AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, is pleased to announce that its wholly owned subsidiary Honeywood LLC ("Honeywood" has successfully transitioned into its new Berkeley, California based headquarters and production facility. This new Honeywood headquarters complex includes: corporate offices for administrative activities, a substantially improved production facility, and laboratory space for research and development ("R & D" activities. Additionally Honeywood has moved its CO2 extraction machine into this new facility and is gearing up for another production run in the near future. In addition to its Doc Green's topical cannabis cream, which is already available in dispensaries in California, Honeywood has developed Vapura, a soon-to-be-launched medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor.
Tauriga Sciences Inc. Appoints University of Cincinnati Biochemistry Professor Daniel J. Hassett, Ph.D. as Member of Company's Scientific and Medical Advisory Board
GlobeNewswire - Mon Aug 04, 1:13PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company" , a diversified life sciences company, has today announced the appointment of Dr. Daniel Hassett ("Dr. Hassett" as a member of the Company's Scientific and Medical Advisory Board. Dr. Hassett was the Co-Founder and Chairman of the Scientific Advisory Board of Pilus Energy LLC ("Pilus Energy" prior to Tauriga's acquisition of wholly-owned subsidiary Pilus Energy on January 28, 2014. Dr. Hassett's microbiology expertise is of great importance as the Company advances its five-phase commercial pilot test with the EPA's Test and Evaluation facility and the Metropolitan Sewer District of Greater Cincinnati to scale up Pilus Energy's synthetic biology platform for generating value from wastewater.
Tauriga Sciences, Inc. Approved to Continue Trading on OTCQB Marketplace
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company" , a diversified life sciences company, today announced it received notice of approval effective as of July 29, 2014 from OTC Markets Group, Inc. ("OTC Markets" to continue trading on the OTCQB Marketplace. The notice confirms that Tauriga submitted all the mandatory documents and has successfully met all the initial requirements for the OTCQB.
Tauriga Sciences Inc. Introduces First Cannabis Complements Product in Colorado
GlobeNewswire - Mon Jul 28, 8:29AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company, is introducing the first supplement in its Cannabis Complements line of dietary supplements and natural wellness products to the Colorado market. Tauriga's Cannabis Complements products do not contain cannabis oil but address health and experiential effects relevant to cannabis users as well as to the general public. The first product, Satietiva, is a natural, amino-acid-based supplement for appetite control. Its proprietary formulation is based on licensed, patented technology and contains only "GRAS" ingredients (the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe" to support the specific neurotransmitter activity associated with appetite control, independent of the cause of increased appetite. Tauriga is partnering with The Mary Jane Group (OTCBB:MJMJ) to introduce Satietiva to guests of The Adagio, a historic Victorian bed & breakfast ("bud & breakfast" in Denver owned and operated by The Mary Jane Group.
Tauriga Sciences, Inc. Responds to Negligent and Misleading Article Published July 16, 2014 by Hotstocked
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or "the Company" , a diversified life sciences company, is responding to a negligent article which disseminated materially false information about the Company. This article titled "Tauriga Sciences Inc. has Turbulent Start to the Week," by Georgi Kamburov was published on July 16, 2014 by Hotstocked. This article was brought to the Company's attention by several shareholders, and the misinformation was so egregious that management believes a public rebuttal is necessary.
Tauriga Sciences enters into license agreement with Targeted Medical Pharma for launch of new cannabis complements product line
M2 - Thu Jul 17, 8:15AM CDT
Life sciences company Tauriga Sciences (Other OTC:TAUG) disclosed on Wednesday the launch of a non-exclusive licensing agreement under its "Cannabis Complements" product line.
Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
GlobeNewswire - Wed Jul 16, 2:31PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company, announced today it has signed a non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical's medical food formulations into dietary supplements as part of Tauriga's "Cannabis Complements" product line. Tauriga's new Cannabis Complements product line will be formally launched later in the summer and consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The products to be offered under the "Cannabis Complements" line will contain "GRAS" ingredients, the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe".
Tauriga Sciences Inc. Completes Acquisition of Honeywood LLC, a California-Based Developer of Medicinal Cannabis Products, Including Doc Green's Cream
GlobeNewswire - Mon Jul 14, 4:21AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company, is pleased to announce that it has successfully completed its acquisition of California-based medicinal cannabis firm Honeywood LLC ("Honeywood" , the formulator for Doc Green's topical cannabis cream and for other products. Under terms of the completed acquisition agreement, Honeywood will operate as a wholly owned subsidiary of Tauriga Sciences Inc., with all future revenues and profits (losses) to be reflected on Tauriga's pro forma financial statements. The final acquisition terms result in stakeholders of Honeywood receiving 15.5% of Tauriga Sciences non-diluted shares of common stock outstanding immediately prior to closing. Honeywood's principals have the opportunity to collectively earn up to an additional aggregate equal to 10% of Tauriga's common stock outstanding (utilizing the same initial Closing Date) upon achieving the following gross revenue based milestones: upon the generation and receipt of $2,000,000 USD of gross revenues derived strictly from the sale and licensing of Honeywood's products, the three Honeywood principals shall each be issued either restricted stock or stock options equal to 1.6666% shares of Common Stock of Tauriga; upon the generation and receipt of an additional $2,000,000 USD ($4,000,000 USD total gross revenues by Honeywood), its three principals shall each be issued an additional 1.6666% shares of Common Stock of Tauriga (each such additional issuance to be set off the outstanding shares immediately prior to the Closing Date).
Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Tauriga Sciences Inc. Wholly Owned Subsidiary Pilus Energy LLC Featured in CNBC Special "States Partner to Spur Innovation in New Industries"
GlobeNewswire - Wed Jun 25, 11:54AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with a proprietary microbial fuel cell technology, today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" has been featured in a CNBC Special by Tom Cunneff, Titled: "States Partner to Spur Innovation in New Industries." The article discusses President Obama's $33 million Jobs and Innovation Accelerator Challenge as well as the public-private partnership between the states of Indiana, Kentucky and Ohio with the goal of bringing a focus and cohesiveness to all the different water entities in this H2O-rich area.
Tauriga Sciences Inc. and Honeywood LLC Successfully Amend Merger Agreement; Closing of Acquisition Remains on Track for July 10, 2014
GlobeNewswire - Mon Jun 23, 3:40AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with a proprietary microbial fuel cell technology, is pleased to announce that its acquisition of Honeywood LLC ("Honeywood", and Doc Green's product lines) will be completed under terms that are significantly less dilutive to Tauriga shareholders than previously announced, as a result of the successful amendment to the Agreement and Plan of Merger, dated March 10, 2014 ("Merger Agreement" . The acquisition is on track to be completed by July 10, 2014, the Closing date originally set forth in the Merger Agreement. As part of Tauriga's customary and continued due diligence of Honeywood LLC, including financials and analysis of the potential of Honeywood's new product lines, the parties have agreed to reduce the Honeywood consideration from 32% of Tauriga's fully-diluted capitalization to 18% of Tauriga's non-diluted shares of common stock outstanding at the time of closing. Tauriga has also agreed to provide an opportunity for Honeywood's principals to collectively earn up to an additional aggregate equal to 10% of Tauriga's common stock outstanding (utilizing the same initial Closing Date) upon achieving certain gross revenue based milestones. These revenue based milestones can be summarized as follows: upon the generation and receipt of $2.0MM of gross revenues derived strictly from the sale of Doc Green's and Honeywood's products, the three Honeywood principals shall each be issued either restricted stock or stock options equal to an additional 1.6666% shares of Common Stock of Tauriga. Upon the generation and receipt of an additional $2.0MM ($4.0 MM total gross revenues by Honeywood), its three principals shall each be issued an additional 1.6666% shares of Common Stock of Tauriga (each such additional issuance to be set off the outstanding shares at the initial Closing Date).
Tauriga Sciences Inc. Fully Repays and Retires the Convertible Note Held by Group 10 Holdings LLC for Principal Amount of $157,500 USD
GlobeNewswire - Mon Mar 31, 10:41AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include active license agreements, topical medicinal cannabis lotions, and a proprietary microbial fuel cell technology, today announced that it has fully repaid a convertible note ("the note" held by Group 10 Holdings, LLC ("Group 10 Holdings" for the principal amount of $157,500 USD. On September 30, 2013, Tauriga borrowed $157,500 USD from Group 10 while the Company was negotiating with Bacterial Robotics LLC ("Bacterial Robotics" to acquire synthetic biology pioneer Pilus Energy LLC ("Pilus Energy" . This capital infusion was crucial at that time, to provide the Company with the resources to execute the definitive merger agreement with Pilus Energy in late November 2013. The signing of that definitive agreement and the subsequent completion of the Pilus Energy acquisition on January 28, 2014 were unquestionably the catalysts that laid the foundation for future success. Including accrued interest and contractual buyout premiums, the note was fully repaid and retired for a cash payment of $225,487.36 USD. Therefore, there will be absolutely no share conversions owed to Group 10 Holdings in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet.
Tauriga Sciences Inc. Completes $800,000 USD Equity Private Placement Priced at 6 Cents per Share
GlobeNewswire - Mon Mar 31, 5:22AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include active license agreements, interests in a topical medicinal cannabis company, and a proprietary microbial fuel cell technology, has today announced the completion of a $800,000 USD equity private placement at a price of 6 cents per share ("$0.06" to various accredited investors. There were no warrants or registration rights offered in conjunction with this private placement financing. The shares issued pursuant to this private placement are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended.
CBS Outdoor Americas Climbs on First Day of Trading; FDA Advisory Panel Recommends Approval of Exact Sciences Corporation's Cologuard
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
CBS Outdoor Americas Inc. (NYSE: CBSO) - For an in-depth report on CBS Outdoor Americas Inc. follow: www.BullTrends.com/stockquote/CBSO
Tauriga Sciences Inc. Launches $1,700,000 USD Commercial Pilot Test With the EPA and the Metropolitan Sewer District of Greater Cincinnati
GlobeNewswire - Wed Mar 26, 2:02PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include license agreements and a proprietary technology platform in the nanorobotics space, has today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" has commenced a five-phase, $1,700,000 USD commercial pilot test ("commercial pilot" with the Environmental Protection Agency ("EPA" , utilizing Chicago Bridge & Iron Co. (NYSE:CBI) ("CB&I" Federal Services serving as the third-party-contractor through the EPA's Test and Evaluation ("T&E" facility. This five phase commercial pilot will include significant testing of the Pilus Energy Electrogenic Bioreactor ("EBR" synthetic biology platform for generating value from wastewater. This commercial pilot is of great importance to the Company, because it represents the scale up from the benchtop (laboratory) scale to commercial (industrial) scale. The Metropolitan Sewer District of Greater Cincinnati ("MSDGR" , which is co-located with EPA's T&E facility, will host the commercial scale EBR prototype at its main treatment plant in Cincinnati.
Tauriga Sciences Inc. Subsidiary Pilus Energy LLC Receives Approval from the US EPA to Commence Scaled Up Pilot Test
GlobeNewswire - Tue Sep 16, 12:44PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that on September 8, 2014, through its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" , received final approval for its Health and Safety Plan ("H & S Plan" . The approval was granted by the United States Environmental Protection Agency ("EPA" and the project subcontractor Chicago Bridge & Iron (NYSE:CBI) ("CB & I" , which operates the EPA's Test & Evaluation ("T & E" Facility where the next phase of the commercial pilot will take place. This final approval, along with the already approved Quality Assurance Project Plan ("QA Plan" , will enable the Company to commence development scale pilot testing at the EPA T& E Facility. The facility is co-located with the Metropolitan Sewer District of Great Cincinnati's ("MSDGC" largest wastewater treatment plant, on the Mill Creek site, which flows directly into the Ohio river. Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Tauriga Sciences, Inc.
GlobeNewswire - Tue Sep 16, 10:22AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on Tauriga Sciences, Inc. (TAUG-OTC). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
Tauriga Sciences Inc. Executes Investment Banking Agreement With Tokyo, Japan Based Dragoon Capital Inc.
GlobeNewswire - Mon Aug 25, 7:30AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it has entered into an investment banking agreement with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. ("Dragoon" . Through this investment banking agreement, Dragoon has agreed on a best efforts basis to secure the Company a private placement equity capital financing from its extensive base of both Japanese institutional and accredited individual investors. The proceeds from this private placement, if and when complete, should enable the Company to expand its medicinal cannabis and complementary natural wellness businesses as well as provide Pilus Energy with capital as it advances its pilot test program with the Metropolitan Sewer District of Greater Cincinnati ("MSDGC" and the EPA T&E department (Environmental Protection Agency's Testing & Evaluation department). Tauriga Sciences Inc. to Present at Marijuana for Medical Professionals Conference on September 9 in Denver, Colorado
GlobeNewswire - Mon Aug 18, 6:26AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company's Chief Medical Officer, Lawrence A. May, M.D., F.A.C.P., will make a presentation on Tuesday, September 9th, 2014 at 12:15 PM at Marijuana for Medical Professionals Conference being held at the Sherman St Event Center in Denver, CO. Tauriga Sciences Inc. Subsidiary Honeywood LLC's Berkeley, California Based Headquarters and Production Facility Now Operational
GlobeNewswire - Wed Aug 06, 6:50AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, is pleased to announce that its wholly owned subsidiary Honeywood LLC ("Honeywood" has successfully transitioned into its new Berkeley, California based headquarters and production facility. This new Honeywood headquarters complex includes: corporate offices for administrative activities, a substantially improved production facility, and laboratory space for research and development ("R & D" activities. Additionally Honeywood has moved its CO2 extraction machine into this new facility and is gearing up for another production run in the near future. In addition to its Doc Green's topical cannabis cream, which is already available in dispensaries in California, Honeywood has developed Vapura, a soon-to-be-launched medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor. Tauriga Sciences Inc. Appoints University of Cincinnati Biochemistry Professor Daniel J. Hassett, Ph.D. as Member of Company's Scientific and Medical Advisory Board
GlobeNewswire - Mon Aug 04, 1:13PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company, has today announced the appointment of Dr. Daniel Hassett ("Dr. Hassett" as a member of the Company's Scientific and Medical Advisory Board. Dr. Hassett was the Co-Founder and Chairman of the Scientific Advisory Board of Pilus Energy LLC ("Pilus Energy" prior to Tauriga's acquisition of wholly-owned subsidiary Pilus Energy on January 28, 2014. Dr. Hassett's microbiology expertise is of great importance as the Company advances its five-phase commercial pilot test with the EPA's Test and Evaluation facility and the Metropolitan Sewer District of Greater Cincinnati to scale up Pilus Energy's synthetic biology platform for generating value from wastewater. Tauriga Sciences, Inc. Approved to Continue Trading on OTCQB Marketplace
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company, today announced it received notice of approval effective as of July 29, 2014 from OTC Markets Group, Inc. ("OTC Markets" to continue trading on the OTCQB Marketplace. The notice confirms that Tauriga submitted all the mandatory documents and has successfully met all the initial requirements for the OTCQB. Tauriga Sciences Inc. Introduces First Cannabis Complements Product in Colorado
GlobeNewswire - Mon Jul 28, 8:29AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company, is introducing the first supplement in its Cannabis Complements line of dietary supplements and natural wellness products to the Colorado market. Tauriga's Cannabis Complements products do not contain cannabis oil but address health and experiential effects relevant to cannabis users as well as to the general public. The first product, Satietiva, is a natural, amino-acid-based supplement for appetite control. Its proprietary formulation is based on licensed, patented technology and contains only "GRAS" ingredients (the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe" to support the specific neurotransmitter activity associated with appetite control, independent of the cause of increased appetite. Tauriga is partnering with The Mary Jane Group (OTCBB:MJMJ) to introduce Satietiva to guests of The Adagio, a historic Victorian bed & breakfast ("bud & breakfast" in Denver owned and operated by The Mary Jane Group. Tauriga Sciences, Inc. Responds to Negligent and Misleading Article Published July 16, 2014 by Hotstocked
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or "the Company"
, a diversified life sciences company, is responding to a negligent article which disseminated materially false information about the Company. This article titled "Tauriga Sciences Inc. has Turbulent Start to the Week," by Georgi Kamburov was published on July 16, 2014 by Hotstocked. This article was brought to the Company's attention by several shareholders, and the misinformation was so egregious that management believes a public rebuttal is necessary. Tauriga Sciences enters into license agreement with Targeted Medical Pharma for launch of new cannabis complements product line
M2 - Thu Jul 17, 8:15AM CDT
Life sciences company Tauriga Sciences (Other OTC:TAUG) disclosed on Wednesday the launch of a non-exclusive licensing agreement under its "Cannabis Complements" product line.
Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
GlobeNewswire - Wed Jul 16, 2:31PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, announced today it has signed a non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical's medical food formulations into dietary supplements as part of Tauriga's "Cannabis Complements" product line. Tauriga's new Cannabis Complements product line will be formally launched later in the summer and consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The products to be offered under the "Cannabis Complements" line will contain "GRAS" ingredients, the U.S. Food and Drug Administration's designation for ingredients that are "Generally Recognized as Safe". Tauriga Sciences Inc. Completes Acquisition of Honeywood LLC, a California-Based Developer of Medicinal Cannabis Products, Including Doc Green's Cream
GlobeNewswire - Mon Jul 14, 4:21AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company, is pleased to announce that it has successfully completed its acquisition of California-based medicinal cannabis firm Honeywood LLC ("Honeywood" , the formulator for Doc Green's topical cannabis cream and for other products. Under terms of the completed acquisition agreement, Honeywood will operate as a wholly owned subsidiary of Tauriga Sciences Inc., with all future revenues and profits (losses) to be reflected on Tauriga's pro forma financial statements. The final acquisition terms result in stakeholders of Honeywood receiving 15.5% of Tauriga Sciences non-diluted shares of common stock outstanding immediately prior to closing. Honeywood's principals have the opportunity to collectively earn up to an additional aggregate equal to 10% of Tauriga's common stock outstanding (utilizing the same initial Closing Date) upon achieving the following gross revenue based milestones: upon the generation and receipt of $2,000,000 USD of gross revenues derived strictly from the sale and licensing of Honeywood's products, the three Honeywood principals shall each be issued either restricted stock or stock options equal to 1.6666% shares of Common Stock of Tauriga; upon the generation and receipt of an additional $2,000,000 USD ($4,000,000 USD total gross revenues by Honeywood), its three principals shall each be issued an additional 1.6666% shares of Common Stock of Tauriga (each such additional issuance to be set off the outstanding shares immediately prior to the Closing Date). Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Tauriga Sciences Inc. Wholly Owned Subsidiary Pilus Energy LLC Featured in CNBC Special "States Partner to Spur Innovation in New Industries"
GlobeNewswire - Wed Jun 25, 11:54AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with a proprietary microbial fuel cell technology, today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" has been featured in a CNBC Special by Tom Cunneff, Titled: "States Partner to Spur Innovation in New Industries." The article discusses President Obama's $33 million Jobs and Innovation Accelerator Challenge as well as the public-private partnership between the states of Indiana, Kentucky and Ohio with the goal of bringing a focus and cohesiveness to all the different water entities in this H2O-rich area. Tauriga Sciences Inc. and Honeywood LLC Successfully Amend Merger Agreement; Closing of Acquisition Remains on Track for July 10, 2014
GlobeNewswire - Mon Jun 23, 3:40AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with a proprietary microbial fuel cell technology, is pleased to announce that its acquisition of Honeywood LLC ("Honeywood", and Doc Green's product lines) will be completed under terms that are significantly less dilutive to Tauriga shareholders than previously announced, as a result of the successful amendment to the Agreement and Plan of Merger, dated March 10, 2014 ("Merger Agreement" . The acquisition is on track to be completed by July 10, 2014, the Closing date originally set forth in the Merger Agreement. As part of Tauriga's customary and continued due diligence of Honeywood LLC, including financials and analysis of the potential of Honeywood's new product lines, the parties have agreed to reduce the Honeywood consideration from 32% of Tauriga's fully-diluted capitalization to 18% of Tauriga's non-diluted shares of common stock outstanding at the time of closing. Tauriga has also agreed to provide an opportunity for Honeywood's principals to collectively earn up to an additional aggregate equal to 10% of Tauriga's common stock outstanding (utilizing the same initial Closing Date) upon achieving certain gross revenue based milestones. These revenue based milestones can be summarized as follows: upon the generation and receipt of $2.0MM of gross revenues derived strictly from the sale of Doc Green's and Honeywood's products, the three Honeywood principals shall each be issued either restricted stock or stock options equal to an additional 1.6666% shares of Common Stock of Tauriga. Upon the generation and receipt of an additional $2.0MM ($4.0 MM total gross revenues by Honeywood), its three principals shall each be issued an additional 1.6666% shares of Common Stock of Tauriga (each such additional issuance to be set off the outstanding shares at the initial Closing Date). Tauriga Sciences Inc. Fully Repays and Retires the Convertible Note Held by Group 10 Holdings LLC for Principal Amount of $157,500 USD
GlobeNewswire - Mon Mar 31, 10:41AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include active license agreements, topical medicinal cannabis lotions, and a proprietary microbial fuel cell technology, today announced that it has fully repaid a convertible note ("the note" held by Group 10 Holdings, LLC ("Group 10 Holdings" for the principal amount of $157,500 USD. On September 30, 2013, Tauriga borrowed $157,500 USD from Group 10 while the Company was negotiating with Bacterial Robotics LLC ("Bacterial Robotics" to acquire synthetic biology pioneer Pilus Energy LLC ("Pilus Energy" . This capital infusion was crucial at that time, to provide the Company with the resources to execute the definitive merger agreement with Pilus Energy in late November 2013. The signing of that definitive agreement and the subsequent completion of the Pilus Energy acquisition on January 28, 2014 were unquestionably the catalysts that laid the foundation for future success. Including accrued interest and contractual buyout premiums, the note was fully repaid and retired for a cash payment of $225,487.36 USD. Therefore, there will be absolutely no share conversions owed to Group 10 Holdings in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet. Tauriga Sciences Inc. Completes $800,000 USD Equity Private Placement Priced at 6 Cents per Share
GlobeNewswire - Mon Mar 31, 5:22AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include active license agreements, interests in a topical medicinal cannabis company, and a proprietary microbial fuel cell technology, has today announced the completion of a $800,000 USD equity private placement at a price of 6 cents per share ("$0.06" to various accredited investors. There were no warrants or registration rights offered in conjunction with this private placement financing. The shares issued pursuant to this private placement are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended. CBS Outdoor Americas Climbs on First Day of Trading; FDA Advisory Panel Recommends Approval of Exact Sciences Corporation's Cologuard
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
CBS Outdoor Americas Inc. (NYSE: CBSO) - For an in-depth report on CBS Outdoor Americas Inc. follow: www.BullTrends.com/stockquote/CBSO
Tauriga Sciences Inc. Launches $1,700,000 USD Commercial Pilot Test With the EPA and the Metropolitan Sewer District of Greater Cincinnati
GlobeNewswire - Wed Mar 26, 2:02PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include license agreements and a proprietary technology platform in the nanorobotics space, has today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" has commenced a five-phase, $1,700,000 USD commercial pilot test ("commercial pilot" with the Environmental Protection Agency ("EPA" , utilizing Chicago Bridge & Iron Co. (NYSE:CBI) ("CB&I" Federal Services serving as the third-party-contractor through the EPA's Test and Evaluation ("T&E" facility. This five phase commercial pilot will include significant testing of the Pilus Energy Electrogenic Bioreactor ("EBR" synthetic biology platform for generating value from wastewater. This commercial pilot is of great importance to the Company, because it represents the scale up from the benchtop (laboratory) scale to commercial (industrial) scale. The Metropolitan Sewer District of Greater Cincinnati ("MSDGR" , which is co-located with EPA's T&E facility, will host the commercial scale EBR prototype at its main treatment plant in Cincinnati. 
